The proposed transaction is estimated at $10.1 billion, according to a Nov. 30 AbbVie news release.
ImmunoGen’s flagship drug, Elahere, a first-in-class antibody-drug conjugate (ADC), has been approved for platinum-resistant ovarian cancer to target solid tumors.
“The addition of ImmunoGen’s pipeline, platform, and expertise to AbbVie’s oncology portfolio is an exciting opportunity for the combined companies to advance innovation in ADCs,” Mark Enyedy, president and CEO of ImmunoGen stated in the release. “This transaction is the culmination of our 40-year commitment to develop and deliver the next-generation of ADCs and more good days for people living with cancer.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
